EVOQ Remedies Ltd
EVOQEVOQ Remedies Ltd
EVOQ
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | 0.79 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
EVOQ Remedies Limited is engaged in the pharmaceutical business. The Company is engaged in marketing, trading, and distribution of pharmaceutical formulation products such as anti-biotic drugs, anti-malarial drugs, anti-allergic and anti-cold drugs, analgesic/ antipyretic and anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastrointestinal drugs, steroids, gynecology drugs, calcium, multivitamins, antioxidants, and injections. The Company also deals in the trading of active pharmaceutical ingredients (APIs). The Company's products include Abacavir Sulphate, Acetazolamide, Acyclovir, Adefovir Dipivoxil Allylestrenole, Alpha Beta Arteether, Alpha Lipoic Acid, Alprazolam, Amisulpride, Amoxycillin Trihydrate, Ampicillin Trihydrate, Artemether, Atracurium Besylate, Azathioprine, Azithromycin, Balofloxacin, Bendamustine, Biotin, Bosentan, Brimonidine, Bezafibrate Mupirocin, Mycophenolate, Mycophenolate, Nadifloxacin, Naltrexone HCL and more.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3.25 | 9.07 | 10.02 | 16.78 | 26.41 | 6.31 | — | |||||||
Raw Materials | 3.26 | 9.08 | 7.94 | 14.41 | 20.58 | 2.65 | — | |||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.03 | 0.01 | 0.05 | 0.01 | ||||||||
| Employee Cost | 0.00 | 0.01 | 0.01 | 0.18 | 0.20 | 0.08 | ||||||||
| Selling & Administrative Expenses | 0.01 | 0.01 | 1.16 | 1.32 | 4.50 | 3.98 | ||||||||
| Operating & Other expenses | -0.03 | -0.03 | -0.07 | -0.59 | -1.21 | -1.03 | ||||||||
EBITDA | 0.01 | 0.00 | 0.95 | 1.45 | 2.29 | 0.62 | — | |||||||
| Depreciation/Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | — | |||||||
| PBIT | 0.01 | 0.00 | 0.95 | 1.45 | 2.29 | 0.61 | — | |||||||
| Interest & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | |||||||
| PBT | 0.01 | 0.00 | 0.95 | 1.45 | 2.29 | 0.61 | — | |||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.24 | 0.37 | 0.67 | 0.16 | — | |||||||
| Net Income | 0.01 | 0.00 | 0.71 | 1.08 | 1.62 | 0.45 | — | |||||||
| EPS | 0.14 | 0.00 | 10.00 | 1.51 | 1.19 | 0.33 | — | |||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | |||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| EVOQ Remedies Ltd | 44.27 | 0.79 | — |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare EVOQ with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 9.32%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
EVOQ has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeEvoq Remedies announced that the Annual General Meeting (AGM) of the company will be held on 28 September 2024.Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 14.19%, vs industry avg of 9.03%
Constant Market Share
Over the last 5 years, market share stayed at 0%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 114.11%, vs industry avg of 15.28%